Literature DB >> 21977135

The importance of clinical application of molecular biomarkers in bladder cancer detection.

Raluca Dumache1, Maria Puiu, Dana David, Marinela Popovici, Adriana Kaycsa, Serban Negru, Florin Miclea.   

Abstract

It is known that high throughput technologies facilitate the identification of new molecular targets and biomarkers specific for bladder cancer.The new field of molecular medicine promises that clinical outcomes will be improved by directing therapy toward the molecular mechanisms and targets associated with the growth of the patient's tumor.The great challenge remains to improve the measurement of these targets and to translate this wealth of discovery into clinical management of bladder cancer.

Entities:  

Keywords:  DNA methylation; biomarkers; bladder cancer; tumor suppressor genes

Year:  2010        PMID： 21977135      PMCID： PMC3150003     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


  16 in total

Review 1.  Urothelial tumorigenesis: a tale of divergent pathways.

Authors:  Xue-Ru Wu
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.

Authors:  Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

Review 3.  Cancer epigenetics.

Authors:  Peter W Laird
Journal:  Hum Mol Genet       Date:  2005-04-15       Impact factor: 6.150

Review 4.  Diagnosis and management of superficial bladder cancer.

Authors:  C L Amling
Journal:  Curr Probl Cancer       Date:  2001 Jul-Aug       Impact factor: 3.187

5.  Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.

Authors:  Sarah V Williams; Kathryn D Sibley; Alison M Davies; Hiroyuki Nishiyama; Nick Hornigold; Jane Coulter; Wendy J Kennedy; Amy Skilleter; Tomonori Habuchi; Margaret A Knowles
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

6.  Loss of heterozygosity analysis on chromosome 5p defines 5p13-12 as the critical region involved in tumor progression of bladder carcinomas.

Authors:  M Böhm; R Kleine-Besten; I Wieland
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

Review 7.  The role of E-cadherin-catenin complex: more than an intercellular glue?

Authors:  K J Harrington; K N Syrigos; K J Harington
Journal:  Ann Surg Oncol       Date:  2000-12       Impact factor: 5.344

8.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

Authors:  James W F Catto; Abdel-Rahmene Azzouzi; Ishtiaq Rehman; Kenneth M Feeley; Simon S Cross; Najla Amira; Gaelle Fromont; Mathilde Sibony; Oliver Cussenot; Mark Meuth; Freddie C Hamdy
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

9.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss.

Authors:  P Cairns; L Mao; A Merlo; D J Lee; D Schwab; Y Eby; K Tokino; P van der Riet; J E Blaugrund; D Sidransky
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

10.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

Authors:  Sunanda J Chatterjee; Ram Datar; David Youssefzadeh; Ben George; Peter J Goebell; John P Stein; Lillian Young; Shan-Rong Shi; Conway Gee; Susan Groshen; Donald G Skinner; Richard J Cote
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.